At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
RPh201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
In Brief
A Phase 2 clinical trial evaluating RPh201 and Placebo for Non-arteritic Ischemic Optic Neuropathy and Optic Nerve Injuries. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the treatment phase to another 13 weeks (26 weeks total), and at the follow-up visit at 3 month after end of treatment in patients with optic nerve neuropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartFeb 2014
Primary CompletionAug 2016
Study CompletionDec 2016
TodayJul 2026
First PostedJan 24, 2014
Enrollment StartFeb 1, 2014
Primary CompletionAug 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12.4 years ago
Interventions
RPh201drug
SC injection twice a week during 13/26 weeks
Placebodrug
SC injection twice a week during 13/26 weeks